Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer

NCT02069145 is registered in ClinicalTrials.gov with OncoMed Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02069145
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02069145 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer
Lead sponsor
OncoMed Pharmaceuticals, Inc.
Phase
Phase 1
Overall status
Completed
Start date
January 31, 2014
Completion date
July 31, 2017
Enrollment
10 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular cancer, liver cancer